Patents by Inventor Joyce A. Taylor

Joyce A. Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
    Patent number: 10919973
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: February 16, 2021
    Assignees: KOBENHAVNS UNIVERRSITET, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • GENERATION OF A CANCER-SPECIFIC IMMUNE RESPONSE TOWARD MUC1 AND CANCER SPECIFIC MUC1 ANTIBODIES
    Publication number: 20180334507
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Application
    Filed: June 12, 2018
    Publication date: November 22, 2018
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
    Patent number: 10017576
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: July 10, 2018
    Assignees: Københavns Universitet, Cancer Research Technology Limited
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • GENERATION OF A CANCER-SPECIFIC IMMUNE RESPONSE TOWARD MUC1 AND CANCER SPECIFIC MUC1 ANTIBODIES
    Publication number: 20160176975
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Application
    Filed: February 10, 2016
    Publication date: June 23, 2016
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
    Patent number: 9359436
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: June 7, 2016
    Assignees: Københavns Universitet, Cancer Research Technology Limited
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • GENERATION OF A CANCER-SPECIFIC IMMUNE RESPONSE TOWARD MUC1 AND CANCER SPECIFIC MUC1 ANTIBODIES
    Publication number: 20150065692
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Application
    Filed: November 12, 2014
    Publication date: March 5, 2015
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Query transformation for masking data within database objects
    Patent number: 8930410
    Abstract: According to one embodiment of the present invention, a system processes a database query, and comprises a computer system including at least one processor. The system identifies one or more expressions within the database query utilizing a database object with value masking. Masking requirements are determined for each identified expression and the database object utilized by that identified expression is replicated to provide masked and actual versions of that database object in response to the masking requirements for that expression including masked values and actual values of that database object. The value masking of the database object is applied to the identified expressions within the database query based on the determined masking requirements to produce search results with masked values for the database query. Embodiments of the present invention further include a method and computer program product for processing a database query in substantially the same manner described above.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: January 6, 2015
    Assignee: International Business Machines Corporation
    Inventors: Eric L. Alton, Thomas A. Beavin, Harley W. Boughton, Yao-Ching S. Chen, Curt L. Cotner, Yuping Ding, Dengfeng Gao, Gerald G. Kiernan, Xun Li, Irene C. Liu, Walid Rjaibi, Gregory R. Stager, Joyce A. Taylor, Timothy J. Vincent, Liyan Zhou
  • Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
    Patent number: 8912311
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: December 16, 2014
    Assignees: Københavns Universitet, Cancer Research Technology Limited
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • GENERATION OF A CANCER-SPECIFIC IMMUNE RESPONSE TOWARD MUC1 AND CANCER SPECIFIC MUC1 ANTIBODIES
    Publication number: 20140005366
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Application
    Filed: April 16, 2013
    Publication date: January 2, 2014
    Applicants: Cancer Research Technology Limited, Københavns Universitet
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
    Patent number: 8440798
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: May 14, 2013
    Assignees: Københavns Universitet, Cancer Research Technology Limited
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • Query Transformation for Masking Data Within Database Objects
    Publication number: 20130086088
    Abstract: According to one embodiment of the present invention, a system processes a database query, and comprises a computer system including at least one processor. The system identifies one or more expressions within the database query utilizing a database object with value masking. Masking requirements are determined for each identified expression and the database object utilized by that identified expression is replicated to provide masked and actual versions of that database object in response to the masking requirements for that expression including masked values and actual values of that database object. The value masking of the database object is applied to the identified expressions within the database query based on the determined masking requirements to produce search results with masked values for the database query. Embodiments of the present invention further include a method and computer program product for processing a database query in substantially the same manner described above.
    Type: Application
    Filed: October 3, 2011
    Publication date: April 4, 2013
    Applicant: International Business Machines Corporation
    Inventors: Eric L. Alton, Thomas A. Beavin, Harley W. Boughton, Yao-Ching S. Chen, Curt L. Cotner, Yuping Ding, Dengfeng Gao, Gerald G. Kiernan, Xun Li, Irene C. Liu, Walid Rjaibi, Gregory R. Stager, Joyce A. Taylor, Timothy J. Vincent, Liyan Zhou
  • Method of identifying a MHC class I restricted T cell response
    Patent number: 7892828
    Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: February 22, 2011
    Assignees: Transgene S.A., Imperial Cancer Research Technology. Ldt.
    Inventors: Joyce Taylor-Papadimitriou, Lukas Carl Heukamp, Rienk Offringa, Cornelis Johanna Maria Melief, Bruce Acres, Mireille Thomas
  • METHOD OF IDENTIFYING A MHC CLASS I RESTRICTED T CELL RESPONSE
    Publication number: 20100255501
    Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.
    Type: Application
    Filed: October 13, 2009
    Publication date: October 7, 2010
    Applicants: Transgene S.A., Imperial Cancer Research Technology, Ltd.
    Inventors: Joyce Taylor-Papadimitriou, Lukas Carl Heukamp, Rienk Offringa, Cornelis Johanna Maria Melief, Bruce Acres, Mireille Thomas
  • GENERATION OF A CANCER-SPECIFIC IMMUNE RESPONSE TOWARD MUC1 AND CANCER SPECIFIC MUC1 ANTIBODIES
    Publication number: 20100034825
    Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
    Type: Application
    Filed: October 4, 2007
    Publication date: February 11, 2010
    Applicants: Kobenhavns Universitet, Cancer Research Tecnology Limited
    Inventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sorensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
  • METHOD OF IDENTIFYING A MHC CLASS I RESTRICTED T CELL RESPONSE
    Publication number: 20080227082
    Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.
    Type: Application
    Filed: March 4, 2008
    Publication date: September 18, 2008
    Applicants: Transgene S.A., Imperial Cancer Research Technology, Ltd.
    Inventors: Joyce TAYLOR-PAPADIMITRIOU, Lukas Carl Heukamp, Rienk Offringa, Cornelis Johanna Maria Melief, Bruce Acres, Mireille Thomas
  • Antigens derived from the core protein of the human mammary epithelial mucin
    Publication number: 20050260604
    Abstract: An expression vector is used to express a polypeptide comprising the core protein of a human polymorphic epithelial mucin, which core protein is specifically bound by monoclonal antibody. SM3. The vector may be used to elicit an immune response in a subject, and to thereby immunize that subject against a disease.
    Type: Application
    Filed: January 29, 2004
    Publication date: November 24, 2005
    Inventors: Joyce Taylor-Papadimitriou, Sandra Gendler, Joy Burchell
  • MUC-1 derived peptides
    Publication number: 20050142640
    Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.
    Type: Application
    Filed: February 11, 2005
    Publication date: June 30, 2005
    Applicants: Transgene S.A., Imperial Cancer Research Technology, Ltd.
    Inventors: Joyce Taylor-Papadimitriou, Lukas Heukamp, Rienk Offringa, Cornelis Melief, Bruce Acres, Mireille Thomas
  • Breast cancer antigen
    Publication number: 20030211521
    Abstract: A gene encoding a polypeptide, related in sequence to retinoblastoma binding proteins 1 and 2, which is expressed in breast cancer, therapeutic and diagnostic methods relating to this gene and polypeptide.
    Type: Application
    Filed: January 2, 2003
    Publication date: November 13, 2003
    Applicant: IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED
    Inventor: Joyce Taylor-Papadimitriou
  • Probe
    Publication number: 20020071830
    Abstract: An expression vector is used to express a polypeptide comprising the core protein of a human polymorphic epithelial mucin, which core protein is specifically bound by monoclonal antibody. SM3. The vector may be used to elicit an immune response in a subject, and to thereby immunize that subject against a disease.
    Type: Application
    Filed: December 5, 2000
    Publication date: June 13, 2002
    Inventors: Joyce Taylor-Papadimitriou, Sandra Gendler, Joy Burchell
  • Antigens derived from the core protein of the human mammary epithelial mucin
    Patent number: 6222020
    Abstract: Antigens are derived from the tandem repeat sequence of the core protein of a human polymorphic epithelial mucin. These antigens include a core protein epitope which is recognized by certain antibodies which also bind certain carcinoma antigens, but not fully processed HPEM glycoprotein as produced by the normal lactating human mammary gland.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 24, 2001
    Assignee: Imperial Cancer Research Technology Limited
    Inventors: Joyce Taylor-Papadimitriou, Sandra Gendler, Joy Burchell